Improving Adherence Across Complex Biologic Therapies

Biologic therapies often require complex treatment schedules and a high level of patient engagement to succeed. However, support programs are often impersonal, static, and dependent on clinical oversight. 

Lash Group, a patient support organization focused on specialty and biologic therapies, partnered with Medisafe to integrate a Digital Drug Companion that delivered personalized support across the therapy journey. Focused on the critical first 90 days, the program provided dynamic engagement and on-demand resources between clinical touchpoints.

Understanding the Behavioral Drivers Behind Biologic Therapy Engagement

Within the Digital Drug Companion user population, several key findings emerged over the program timeframe related to patient persistence behaviors.

• Meaningful improvements in patient adherence emerged during the critical first phase of therapy
• Engagement levels increased as patients received more consistent, personalized support throughout their treatment journey
• Care teams were able to extend support more efficiently, without adding additional workload
• Patients reported a more seamless and supportive experience across every stage of therapy

Together, these insights reinforce how biologic therapy persistence is shaped by early engagement patterns and personalized support throughout treatment.

The Gaps in Traditional Biologic Patient Support Programs

The findings suggest that adherence to biologic therapies is positively connected to a curated engagement strategy. Yet many support programs are not structured to respond in a dynamic way.

Without a deeper understanding of evolving needs across biologic therapy populations, support programs risk missing early signals of disengagement and overlooking opportunities for timely intervention at critical points in the patient journey.

Behavioral Intelligence for Better Adherence and Support

Built on 12+ years of real-world patient behavior data and millions of managed doses, Medisafe helps pharmaceutical organizations deliver personalized, behavior-driven engagement at scale.

By understanding the factors that influence biologic medication adherence and responding with timely, contextual support, pharma teams can strengthen patient programs and drive better outcomes across portfolios.

New Insights Into Biologic Patient Behavior

In our latest analysis of Digital Drug Companion users in biologic therapies, we examine how support influences persistence.

The findings provide organizations with a clearer view of the drivers shaping adherence and highlight opportunities to strengthen engagement through dynamic support programs.